Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

HCA · Q1 2026 Earnings

HCA Healthcare

Reported April 24, 2026

30-second summary

Revenue grew 4.3% YoY to $19.11B with same-facility equivalent admissions up just 1.3% and outpatient surgery cases down 1.7% — well below the FY2026 2–3% volume guide. Management reaffirmed full-year revenue ($76.5–80B), EPS ($29.10–31.50), and EBITDA ($15.55–16.45B) by leaning on a $120M-above-plan supplemental payments tailwind and asserting "the balance of the year is largely back on our original plan." The reaffirmation is intact on paper; the quality of the print underneath it is not, and three operational guide lines from January (capex, net income, OCF) quietly disappeared from disclosure.

Headline numbers

EPS

Q1 FY2026

$7.15

Revenue

Q1 FY2026

$19.11B

+4.3% YoY

Free cash flow

Q1 FY2026

$0.90B

Operating margin

Q1 FY2026

12.0%

Key financials

Q1 FY2026

Metric	Q1 FY2026	YoY	Q4 FY2025	QoQ
Revenue	$19.11B	+4.3%	$19.51B	-2.1%
EPS	$7.15	—	$8.01	-10.7%
Operating margin	12.0%	—	—	—
Free cash flow	$0.90B	—	—	—

Guidance

HCA Healthcare reaffirms full-year FY2026 guidance across revenue, EPS, and EBITDA despite softer Q1 volume dynamics; management signals confidence that 'balance of year is largely back on original plan' with 2–3% volume growth expected in remaining three quarters.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

New guidance

Metric	Period	Guide	YoY
Medicaid supplemental payment net benefit change	FY2026	decline of $50 million to $250 million versus prior year	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Capital Expenditures (ex. acquisitions)	FY2026	$5.0 billion to $5.5 billion	Withdrawn — no replacement	—	Withdrawn
Net Income Attributable to HCA Healthcare, Inc.	FY2026	$6.495 billion to $7.035 billion	Withdrawn — no replacement	—	Withdrawn
Cash Flow from Operations	FY2026	$12 billion to $13 billion	Withdrawn — no replacement	—	Withdrawn

Reaffirmed unchanged this quarter: Revenue ($76.5 billion to $80.0 billion), Diluted EPS ($29.10 to $31.50), Adjusted EBITDA ($15.550 billion to $16.450 billion), Exchange-related EBITDA impact ($600 million to $900 million), Equivalent Admissions Growth (2% to 3%), Adjusted EBITDA Margin (Slightly above 20%)

Other KPIs

Q1 FY2026

Segment	Q1 FY2026
Same Facility Emergency Room Visits Growth	0.3%
Same Facility Inpatient Surgery Cases Growth	-0.3%
Same Facility Outpatient Surgery Cases Growth	-1.7%
Adjusted EBITDA	$3.802 billion
Adjusted EBITDA Margin	19.9%
Operating Cash Flow	$2.014 billion
Capital Expenditures	$1.119 billion
Share Repurchases	3.157 million shares for $1.571 billion

Management tone

Q1-2025 policy risk emerges → Q2-2025 volume guide cut → Q3-2025 2026 deferred → Q4-2025 headwinds quantified, capital deployment accelerated → Q1-2026 narrative defense on a soft print.

From quantified resiliency confidence in January to qualitative reassurance this quarter. Three months ago management framed the $400M resiliency program as the explicit, sized offset to a $600–900M exchange headwind — every major exposure carried a number. This quarter the resiliency program is barely audible: "Does it have some upside in some areas? Yes, Could there be some pressures in other areas? Of course. So when we put it together, we feel like we're on the program that we estimated at the beginning of the year." The shift from "$400 million in incremental cost savings" specificity to "we feel like we're on the program" qualitative reassurance is the most material tonal change in the print. The $400M number was never reiterated.

From "long-term 2 to 3 percent growth range" in January to "we believe that we will be able to run between 2% to 3% volume growth in the next three quarters." Last quarter HCA already weakened the equivalent admissions guide from a numeric annual target to "long-term" framing. This quarter, with Q1 printing at 1.3%, management pivots again — now committing to 2–3% growth only over the remaining three quarters rather than the full year. The arithmetic is unforgiving: hitting 2% FY equivalent admissions growth off a 1.3% Q1 requires ~2.2% in each of the next three quarters; hitting the 3% high end requires ~3.6%. The "outlier quarter" frame is doing a lot of work.

From supplemental payments as a quantified headwind in January to a partial bailout in Q1. Three months ago the $250–450M YoY decline in supplemental payments was disclosed as a known guide drag. This quarter, Q1 supplemental payments came in $120M above internal plan, and management used that flexibility to narrow the full-year decline range to $50–250M rather than raise the EBITDA guide. The treatment confirms the Q3-2025 reframe: supplementals are no longer a flow-through to earnings, they're a reserve to absorb operational misses.

Hedging language density spiked. "It's probably a little early to declare," "it's pretty nascent... early to call, whether it's a sustained trend," "generally in line with our expectations," "could there be some pressures in other areas? Of course," "we still do not know how this policy will play out." The exchange environment is explicitly described as "dynamic and has not fully settled" — three months after January's confident quantification of the headwind. The denial-and-underpayment commentary ("we have a long way to go") frames revenue cycle pressure as a multi-year industry issue rather than a contained 2026 item.

The defensive anchor quote. "We view the $180 million headline in the quarter as being temporal and not structural, so we don't think that repeats." This is the entire reaffirmation thesis in one sentence — and the explicit "we don't think" hedge is the tell. Management is asking investors to underwrite that a $180M operational shortfall is non-recurring while simultaneously withdrawing the capex, net income, and OCF guide lines that would let investors verify the assertion.

Recurring themes management leaned on this quarter:

Payer mix deterioration from exchange disruption and Medicaid volatilityUnpredictable seasonal patterns and volume headwinds offset by supplemental payment windfallsAI and digital transformation implementation with early productivity gainsResiliency program cost management offsetting revenue pressuresLabor constraints and elevated operating costs in hurricane-impacted marketsDenial and underpayment escalation from payers requiring proactive revenue cycle management

Risks management surfaced:

Exchange environment remaining dynamic and unsettled, with potential for further payer mix deteriorationMedicaid conversion slowdown potentially driven by immigration concerns, durability unknownFlorida supplemental payment program approval delayed, timing uncertain despite positive outlookIncreased payer denials and underpayments, particularly from Medicare Advantage plansNorth Carolina workforce deficit driving elevated labor costs and operational pressures

Answers to last quarter's watch list

Q1 2026 progress on the $400M resiliency target — No quantified Q1 contribution disclosed. Management offered only qualitative reassurance ("we feel like we're on the program") and explicitly hedged the AI/case management work as "pretty nascent... early to call, whether it's a sustained trend." The $400M number was not reiterated. With Q1 EBITDA margin at 19.9% — below the FY "slightly above 20%" frame — the slippage scenario the watch flagged appears to be materializing.

Continue monitoring

Exchange volume decline relative to 15–20% modeled assumption — Partially resolved. Management disclosed Q1 same-facility exchange equivalent admissions declined approximately 15%, at the low end of the modeled 15–20% range, with an estimated $150M Q1 EBITDA impact. The FY $600–900M EBITDA impact range was reaffirmed, but management noted "the exchange environment remains dynamic and has not fully settled" and deferred fuller commentary to Q2.

Continue monitoring

Surgery case trajectory — Resolved negatively. Outpatient surgery cases ran -1.7% in Q1 and inpatient surgeries also turned negative at -0.3%. Management attributed weakness primarily to the respiratory shortfall and winter storm rather than structural mix change, but the 2–3% equivalent admissions FY guide now sits on top of negative growth on both surgery lines.

Resolved negatively

Buyback pacing vs. operating cash flow — Pacing aggressively. Q1 repurchases of $1.571B against $895M of FCF means buybacks ran ~1.76x quarterly FCF, funded by balance sheet rather than operating cash. The withdrawal of the OCF guide line removes management's own anchor for the FCF envelope. Status: Continue monitoring (with caution)

Pending DTP approvals (Florida, Georgia, Virginia) — Partially resolved. Georgia was approved (grandfathered) and Texas's Atlas program was reinstated, together contributing $120M to Q1 net benefit and $200M to the FY revision. Florida remains pending; management said it continues to "feel positive about the prospects for the approval" but timing is uncertain. Status: Continue monitoring on Florida

Adjusted EBITDA margin against "slightly above 20%" framing — Resolved negatively. Q1 margin of 19.9% printed below the FY "slightly above 20%" frame in the very first quarter of the year, down 50bps YoY. Management's reaffirmation requires the next three quarters to average above 20% to hit the FY frame, and Q1 had the $120M supplemental tailwind already in the print.

Resolved negatively

What to watch into next quarter

Whether the three withdrawn guide lines (capex, net income, OCF) return on the Q2 call. Continued absence implies management has lost conviction on the underlying operating model and the $10B buyback narrative no longer rests on a disclosed FCF baseline. Watch specifically for OCF guidance reinstatement — it's the cleanest read on whether the supplemental windfall is masking operating-cash deterioration.

Outpatient surgery cases. Another quarter of negative outpatient surgery growth would force a downward revision of the 2–3% equivalent admissions guide and pull EBITDA toward the low end of $15.55B. Watch whether mix shift reverses or extends.

Equivalent admissions print vs. the 2–3% "next three quarters" commitment. Q2 must come in at ≥2% to keep the FY frame intact off a 1.3% Q1. A second sub-2% quarter would force a formal volume guide cut.

Quantified Q2 contribution from the $400M resiliency program. Management's refusal to size the Q1 contribution while simultaneously asserting "we're on the program" is the credibility test of the print. A specific dollar contribution on the Q2 call — or continued qualitative deflection — will determine whether the FY EBITDA reaffirmation is defensible.

Exchange volume disclosure on the Q2 call. Q1 came in at the low end (~15%) of the 15–20% modeled range. Watch whether subsequent attrition during and after grace-period expiry pushes the realized decline materially higher, which would push the $600–900M EBITDA impact toward the high end and stress the resiliency offset.

Florida supplemental payment program approval and DTP green-lights. Any approval is pure upside; management characterizes the potential Florida revenues as "may be significant." Continued delay tightens the FY supplemental decline range further toward the $250M downside end.

Buyback pacing. $1.571B in Q1 against $895M FCF is balance-sheet-funded. A second quarter of repurchases materially above quarterly FCF, combined with no OCF reinstatement, signals capital return is leveraging up rather than self-funding.

Sources

HCA Healthcare Q1 2026 press release, filed April 24, 2026: https://www.sec.gov/Archives/edgar/data/860730/000119312526174933/hca-ex99_1.htm
Q1 2026 earnings call prepared remarks and Q&A from Sam Hazen (CEO) and Mike Marks (CFO).
Tapebrief Q4 2025, Q3 2025, and Q2 2025 HCA briefs (prior watch list, guidance baselines, and multi-quarter tone arc).

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.